### IN THE SPECIFICATION

Please insert the following as the first sentence following the title:

-- This application is a continuation-in-part of International Application No. PCT/GB98/00217, filed January 26, 1998, designating the United States, which was based on Great Britain Application No. 9701489.8, filed January 24, 1997. --

## IN THE APPLICATION

Please insert the enclosed paper copy of the Sequence Listing in the subject application.

#### REMARKS

The present application is a continuation-in-part of PCT/GB98/00217, designating the United States, filed January 26, 1998, based on Great Britain Application No. 9701489.8, filed January 24, 1997. The specification is amended in accordance with 37 C.F.R. § 1.78(a)(2) to cross-reference related applications.

# **Sequence Listing**

In response to the Notice to Comply with Requirements, Applicants authorize the Commissioner to use the Sequence Listing filed in parent application No. PCT/GB98/00217, in accordance with 37 C.F.R. § 1.821(e). Furthermore, Applicants enclose herewith a paper copy of the properly formatted Sequence Listing as filed in parent application No. PCT/GB98/00217, filed January 26, 1998. A computer readable copy (diskette) of the Sequence Listing is enclosed in accordance with the requirements of 37 C.F.R. § 1.821-1.825. The undersigned states that the content of the enclosed paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing in the parent application submitted in accordance with 37 C.F.R. § 1.821(e) are believed to be the same, and that this submission does not include new matter.

# Restriction under 35 U.S.C. § 121

In the Office Action, restriction is deemed required under 35 U.S.C. § 121 to one of the following groups of claims:

Group I, claims 1-9, 18-20 and 21-27, drawn to proteins and kits containing them;

Group II, claims 10-17, drawn to methods of detection using the protein; and

Group III, claims 28-35, drawn to methods of treatment.

DC01:268262.1 2